
 **Multidisciplinary Bladder Cancer Symposium 2025 | 05/16/2025 8:00 AM Westin Book Cadillac**

Our faculty will discuss disparities in diagnosis and management of bladder cancer, with regards to race, gender and other minorities. Speakers with review evidence based clinical and technical advances, promising clinical trials data, national guidelines and key controversies in the management of bladder cancer. Our keynote speaker will highlight the role of clinicians in providing expert care for bladder cancer, and identify methods in overcoming the disparities. Through leading-edge lectures, case discussion and interactive question and answer sessions, this program will provide participants with an enhanced ability to apply best treatment options into their individual cancer practices.

**Program Goal**

1 Identify, recognize and understand current disparities in bladder cancer care.

2 Implement a multidisciplinary approach to address these disparities in management of bladder cancer

3 Develop a patient-centered approach to the management of bladder cancer

4 Modify current practices to improve inclusion of diverse populations in clinical trials and novel treatments for bladder cancer.

5 Apply principles of bladder cancer management to complex cases

**Target Audience** Internal Medicine, Radiation Oncology, Urology, Hematology / Oncology, Medical Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Clara Hwang, MD, Assistant Professor | Co-Director, Faculty | Grant or research support-Seagen|Grant or research support-Taiho Pharmaceutical|Grant or research support-Exelixis|Grant or research support-Bayer|Grant or research support-AstraZeneca|Other: General Payment (Education)-Genentech (Relationship has ended)|Paid consultant-EMD Sorono (Relationship has ended)|Grant or research support-Genentech (Relationship has ended)|Grant or research support-Merck|Grant or research support-Astellas|Grant or research support-Hengrui|Grant or research support-Scholar Rock|Grant or research support-Fujifilm|Grant or research support-Adcentrx|Consulting Fee-Janssen (Relationship has ended) - 01/22/2025 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 02/07/2025 |
| Evelyn Jiagge, MD, PhD, Dr | Faculty | Grant or research support-Pfizer|Grant or research support-Genentech - 02/16/2025 |
| Philip Philip, MD, PhD | Faculty | Consulting Fee-Advisor, Speaker Beureau, |Grant or research support-Karyopharm (Relationship has ended)|Advisor-Pfizer|Advisor-Seattle Genetics|Consulting Fee-Bayer|Grant or research support-Carcept (Relationship has ended)|Honoraria-Daiichi (Relationship has ended)|Honoraria-Erytech (Relationship has ended)|Honoraria-Incyte|Honoraria-Ipsen (Relationship has ended)|Honoraria-Merck (Relationship has ended)|Honoraria-Novocure (Relationship has ended)|Grant or research support-Rafael (Relationship has ended)|Honoraria-Genetech (Relationship has ended)|Consulting Fee-Trisauls (Relationship has ended)|Advisor-Boston Pharmaceuticals (Relationship has ended)|Honoraria-Servier (Relationship has ended) - 12/11/2024 |
| nabeel shakir, MD | Faculty | Nothing to disclose - 02/09/2025 |
| Johar Raza, MD | Course Director, Faculty | Nothing to disclose - 01/29/2025 |
| Briar Shannon, BSN, RN | Faculty | Honoraria-Storz (Karl Storz) (Relationship has ended) - 02/03/2025 |
| Michelle Clayton, BA | CME Specialist | Nothing to disclose - 01/29/2025 |
| Cheryl Lee, MD | Faculty | Advisor-UroGen (Relationship has ended)|Advisor-Vessica Health|Honoraria-Boston Scientific|Grant or research support-Tsumura - 02/28/2025 |
| Akshay Sood, MD | Faculty | Nothing to disclose - 02/03/2025 |
| Deborah C. Marshall, MD | Faculty | Nothing to disclose - 02/12/2025 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 4.50 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part 2: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Please allow a minimum of 3 days to process this request.